[{"orgOrder":0,"company":"Santa Lucia Foundation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Newly Published Study Funded by the Alzheimer's Drug Discovery Foundation Finds Dopamine Therapy Improves Cognitive Function in Mild-to-Moderate Alzheimer's Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"ITALY","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Rotigotine","moa":"D2 receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Santa Lucia Foundation","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Transdermal Patch","sponsorNew":"Santa Lucia Foundation \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Santa Lucia Foundation \/ Not Applicable"},{"orgOrder":0,"company":"XPhyto","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$1.8 million","upfrontCash":"Undisclosed","newsHeadline":"XPhyto Closes Second Tranche of Financing","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Private Placement","leadProduct":"Rotigotine","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"XPhyto","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Transdermal Patch","sponsorNew":"XPhyto \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"XPhyto \/ Undisclosed"},{"orgOrder":0,"company":"XPhyto","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$3.6 million","upfrontCash":"Undisclosed","newsHeadline":"XPhyto Closes Final Tranche of Fully Subscribed Financing","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Financing","leadProduct":"Rotigotine","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"XPhyto","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Transdermal Patch","sponsorNew":"XPhyto \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"XPhyto \/ Undisclosed"},{"orgOrder":0,"company":"XPhyto","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"XPhyto Reports Excellent Rotigotine In-Vitro\/Ex-Vivo Results for Parkinson's Disease Treatment","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Rotigotine","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"XPhyto","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Patch","sponsorNew":"XPhyto \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"XPhyto \/ Not Applicable"},{"orgOrder":0,"company":"Bionxt Lifesciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioNxt Reports Update on Commercialization of Rotigotine Patch for Treatment of Parkinson's Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Rotigotine","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Bionxt Lifesciences","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Patch","sponsorNew":"Bionxt Lifesciences \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Bionxt Lifesciences \/ Not Applicable"},{"orgOrder":0,"company":"Bionxt Solutions","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"BioNxt Signs Clinical Study Agreement and Commences Manufacture of Clinical Samples for Study of Transdermal Rotigotine Patch for Parkinson\u2019s Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2023","year":"2023","type":"Agreement","leadProduct":"Rotigotine","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"IND Enabling","graph3":"Bionxt Solutions","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Patch","sponsorNew":"Bionxt Solutions \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Bionxt Solutions \/ Undisclosed"},{"orgOrder":0,"company":"Bionxt Solutions","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$2.0 million","upfrontCash":"Undisclosed","newsHeadline":"BioNxt Solutions Closes First Tranche of Financing","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2023","year":"2023","type":"Private Placement","leadProduct":"Rotigotine","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Bionxt Solutions","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Bionxt Solutions \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Bionxt Solutions \/ Undisclosed"},{"orgOrder":0,"company":"Bionxt Solutions","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioNxt Receives Approval for European Clinical Study of Transdermal Rotigotine Patch for Parkinson\u2019s Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Rotigotine","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"IND Enabling","graph3":"Bionxt Solutions","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Patch","sponsorNew":"Bionxt Solutions \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Bionxt Solutions \/ Not Applicable"},{"orgOrder":0,"company":"Bionxt Solutions","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$3.9 million","upfrontCash":"Undisclosed","newsHeadline":"BioNxt Solutions Announces Non-Brokered Private Placement","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2023","year":"2023","type":"Private Placement","leadProduct":"Rotigotine","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"IND Enabling","graph3":"Bionxt Solutions","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Patch","sponsorNew":"Bionxt Solutions \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Bionxt Solutions \/ Undisclosed"},{"orgOrder":0,"company":"Bionxt Solutions","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$3.9 million","upfrontCash":"Undisclosed","newsHeadline":"Bionxt Solutions Announces Closing of First Tranche of Non-Brokered Private Placement","therapeuticArea":"Neurology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2023","year":"2023","type":"Private Placement","leadProduct":"Rotigotine","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"IND Enabling","graph3":"Bionxt Solutions","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Patch","sponsorNew":"Bionxt Solutions \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Bionxt Solutions \/ Undisclosed"},{"orgOrder":0,"company":"Bionxt Solutions","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$3.9 million","upfrontCash":"Undisclosed","newsHeadline":"Bionxt Solutions Announces Closing of Second Tranche of Non-Brokered Private Placement","therapeuticArea":"Neurology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2023","year":"2023","type":"Private Placement","leadProduct":"Rotigotine","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"IND Enabling","graph3":"Bionxt Solutions","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Patch","sponsorNew":"Bionxt Solutions \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Bionxt Solutions \/ Undisclosed"},{"orgOrder":0,"company":"Bionxt Solutions","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$2.0 million","upfrontCash":"Undisclosed","newsHeadline":"BioNxt Solutions Announces Closing of Third and Final Tranche of Non-Brokered Private Placement","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2023","year":"2023","type":"Private Placement","leadProduct":"Rotigotine","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"IND Enabling","graph3":"Bionxt Solutions","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Patch","sponsorNew":"Bionxt Solutions \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Bionxt Solutions \/ Undisclosed"},{"orgOrder":0,"company":"Bionxt Solutions","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$1.2 million","upfrontCash":"Undisclosed","newsHeadline":"XPhyto Closes First Tranche of Financing","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Private Placement","leadProduct":"Rotigotine","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Bionxt Solutions","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Bionxt Solutions \/ Undisclosed","highestDevelopmentStatusID":null,"companyTruncated":"Bionxt Solutions \/ Undisclosed"},{"orgOrder":0,"company":"Bionxt Solutions","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"XPhyto Reports Developments on Rotigotine Patch for Parkinson's Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Rotigotine","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Bionxt Solutions","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Bionxt Solutions \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Bionxt Solutions \/ Not Applicable"},{"orgOrder":0,"company":"Luye Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Luye\u2019s Jinyouping Rotigotine Microspheres Approved for Marketing in China","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Rotigotine","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Luye Pharma","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Luye Pharma \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Luye Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Luye Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Luye Completes Phase I Trial for Rotigotine Microspheres in Japan","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Rotigotine","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Luye Pharma","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Luye Pharma \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Luye Pharma \/ Not Applicable"}]
Find Clinical Drug Pipeline Developments & Deals for rotigotine transdermal patch
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Market Place
Reset All
